Every 10-Q that Theriva Biologics, Inc. (TOVX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TOVX filings page.
Theriva Biologics, Inc. reports that it remains a clinical-stage oncology company focused on its oncolytic adenovirus platform, led by VCN‑01 for pancreatic cancer and retinoblastoma. For the six months ended June 30, 2026, it recorded $300,000 of license revenue from a new out‑license of SYN‑020 and a net loss of $5.3 million, narrower than the prior‑year period.
Cash and cash equivalents totaled $11.3 million, with total assets of $34.9 million and stockholders’ equity of $12.2 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital or strategic transactions. A 2025 restructuring that reduced headcount by 32% is expected to save about $1.8 million annually and, together with other cuts, extend the cash runway into the first quarter of 2027, though current resources only fully cover certain limited trials and obligations.
During the period Theriva entered a license agreement with Rasayana Therapeutics that provided the $300,000 upfront payment and potential future milestones and royalties, continued to benefit from Spanish R&D tax credits, and modestly reduced its contingent consideration liability linked to the VCN acquisition to $9.8 million.
Theriva Biologics, Inc. reported a first-quarter 2026 net loss attributable to common stockholders of $2.0 million, improving from $4.3 million a year earlier, on license revenue of $0.3 million from out-licensing SYN-020 to Rasayana Therapeutics.
Cash and cash equivalents were $14.4 million as of March 31 2026, with total assets of $38.2 million and an accumulated deficit of about $360.8 million. Net cash used in operating activities was $2.5 million for the quarter.
The company received $1.6 million from a Spanish R&D rebate program and raised about $2.3 million via at-the-market stock sales. Management discloses substantial doubt about the ability to continue as a going concern beyond the next 12 months without additional capital, despite cost reductions and an estimated cash runway into the first quarter of 2027.
Theriva Biologics (TOVX) filed its Q3 2025 Form 10‑Q, reporting a net loss of $4.4 million for the quarter and $21.7 million year‑to‑date. Cash and cash equivalents were $7.5 million at September 30, 2025. Total liabilities rose to $24.1 million, while stockholders’ equity declined to $6.7 million.
The company disclosed substantial doubt about its ability to continue as a going concern without additional capital or strategic transactions. Management approved a restructuring on September 28, 2025, including a 32% workforce reduction (about seven employees), estimating $0.52 million in charges and anticipating ~$1.8 million of annual compensation savings. Management stated that $15.5 million of cash in early November 2025 is expected to fund operations through Q4 2026 and into Q1 2027.
Contingent consideration related to the VCN acquisition increased to $10.8 million, and an accrued milestone of $5.5 million is due to Grifols following VIRAGE Phase 2b endpoints; a $6 million payment was partially deferred. The quarter included financing cash inflows from a May 2025 public offering and ATM sales. Shares outstanding were 33,739,643 as of November 7, 2025.
Theriva Biologics, Inc. filed a Form 10-Q reporting total assets of $35.83 million and cash and cash equivalents of $12.12 million as of June 30, 2025. The company recorded a quarterly net loss of $13.06 million and a six-month net loss of $17.38 million, driven by a sharp increase in general and administrative expenses and continued R&D spending. In the period the company met primary survival and safety endpoints in its VIRAGE Phase 2b trial for lead candidate VCN-01, which triggered a contractual milestone obligation and contributed to an increase in contingent consideration to $10.16 million. The acquired in-process R&D (IPR&D) asset is carried at $19.62 million and was tested for impairment with no charge recorded. The company raised gross proceeds of approximately $7.5 million in a May 2025 offering and had cash of about $9.5 million in early August 2025, with management stating that current cash is expected to be sufficient into the first quarter of 2026. The 10-Q discloses substantial doubt about the Company’s ability to continue as a going concern and the need to obtain additional financing or strategic transactions to fund planned clinical activities.